ZA200506499B - Synthesis of 2-cholormethyl-6-methylbenzoic acid esters - Google Patents

Synthesis of 2-cholormethyl-6-methylbenzoic acid esters Download PDF

Info

Publication number
ZA200506499B
ZA200506499B ZA200506499A ZA200506499A ZA200506499B ZA 200506499 B ZA200506499 B ZA 200506499B ZA 200506499 A ZA200506499 A ZA 200506499A ZA 200506499 A ZA200506499 A ZA 200506499A ZA 200506499 B ZA200506499 B ZA 200506499B
Authority
ZA
South Africa
Prior art keywords
alkyl
formula
aryl
compounds
cycloalkyl
Prior art date
Application number
ZA200506499A
Inventor
Claus-Juergen Maier
Tobias Metzenthin
Joachim Graeser
Richard Bicker
Javier Manero
Original Assignee
Aventis Sanofi Deutschland Gmb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Sanofi Deutschland Gmb filed Critical Aventis Sanofi Deutschland Gmb
Publication of ZA200506499B publication Critical patent/ZA200506499B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Description

; 2004/085377 PCT/EP2004/002579
Description
Synthesis of 2-chloromethyl-6-methylbenzoic acid esters 2-Haloalkylbenzoic acid derivatives are used as building blocks for the synthesis of active pharmaceutical ingredients. For various reasons, it is desirable for the use to have storage-stable compounds which can additionally be prepared and purified in a simple manner. These reasons include, for example, the ensuring of a constant quality, the avoidance of frequent checks on the materials to record the product quality, the avoidance of the necessity of cold storage and/or cold transport, easy transfer to production plants and also simple cleaning of used vessels. 2-Bromomethyl-6-methylbenzoic esters (A1 and A2) are known, for example, from WO 00/64888 (R = iBu (A1)) and WO 00/64876 (R = Me (A2)). These compounds are not storage-stable at room temperature, since they cyclize spontaneously to the lactone (B) and in the process, as is well known, release mutagenic alkyl bromides as a by-product.
JO JOH A
CO-0OiBu CO-OCH, 0 Oo (A1) (A2) (B)
The use of these thermally labile substances on the industrial scale is therefore associated with occupational hygiene risks, difficulties and additional costs.
Among other uses, the 2-bromomethyl-6-methylbenzoic esters are of interest as starting materials for the preparation of PPAR agonists, as described, for example, in WO 00/64888, WO 00/64876 and WO 03/020269. Particular mention should be made here of the compounds of the formula (C):
A
J 2
R' 0)
R"
A
O~,-©
COR
(C) where
R is H, C4-Cq2-alkyl, C3-Cg-cycloalkyl, Cg-C12-aryl, C1-C4-alkyl-Cg-C12- aryl or Cs-Cqp-heteroaryl, where, in alkyl and cycloalkyl, one or more
CH2 groups may be replaced by —O- and alkyl, cycloalkyl and aryl may be substituted by halogen,
Y is —(CH2)3-, 1,3-phenylene, 1,3-cyclohexanediyl;
R’ is H, F, Br, CF3, (C1-Cg)-alkyl, O-(C1-Cg)-alkyl, phenyl;
R" is H, (C1-Cg)alkyl, (C1-C3)-alkylphenyl, (Cs-Cg)-cycloalkyl, phenyl,
CFs.
Preference is given to the compounds of formula (C) in which the phenyl ring is substituted by R’ in the m- or p-position. it is thus an object of the invention to find more stable compounds than (A1) and (A2) which do not have the above-outlined disadvantages. In addition, the compounds which can occur in a purity which is not yet sufficient when they are prepared even from a crude product should, in contrast to the compounds of the formulae (A1) and (A2), be purifiable.
This is achieved by the compounds of the formula (I) described below.
The present invention provides the compounds of formula (|)
COR a 3 where
R is H, C4-Cqz-alkyl, C3-Cg-cycloalkyl, Cg-Cq2-aryl, C1-Cs-alkyl-
Ce-C12-aryl or C5-C1p-heteroaryl, and, in alkyl and cycloalkyl, one or more CH2 groups may be replaced by -O-, and alkyl, cycloalkyl and aryl may be substituted by halogen.
Preference is given to the compounds of the formula (I) in which
R is C1-Cg alkyl, C3-Cg-cycloalkyl or C1-C4-alkyl-Cg-C12-aryl, each of which may optionally be substituted by halogen and in which one or two CH2 groups may be replaced by -O-.
Particular preference is given to the compounds of the formula (I) in which
R is C1-Cg alkyl or C4-Cgs-alkyl-Cg-Cq2-aryl, each of which may optionally be substituted by halogen and in which one CH2 group may be replaced by -O-.
Very particular preference is given to the compounds of the formula (I) in which
R is methyl, ethyl, propyl, i-propyl, t-butyl, phenyl, 2-methoxyethyl or benzyl.
Alkyl may be branched or unbranched. Halogen is Cl, Br, |, preferably CI. In this context, heteroaryl refers to 5- to 10 membered aromatic rings which contain from one to four identical or different heteroatoms from the group of
N, O, S, for example pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, furan, thiophene, oxazole, isoxazole, thiazole, isothiazole, triazole, tetrazole, triazine, tetrazine, preference is given to: pyrrole, imidazole, oxazole, thiazole and pyridine.
The present invention also provides a process for preparing the compounds of the formula (1)
a 4
JO
COR
(1) where
R is H, Cq-Cqz-alkyl, C3-Cg-cycloalkyl, Cg-Cq2-aryl, C1-C4-alkyl-
Ce-C12-aryl or C5-Cqp-heteroaryl, and, in alkyl or cycloalkyl, one or more CH2 groups may be replaced by -O-, and alkyl, cycloalkyl and aryl may be substituted by halogen, which comprises reacting dimethylbenzoic esters of the formula (11)
CO,R (in where R is as defined above with a chlorinating reagent, for example sulfuryl chloride, N-chloro- succinimide (NCS), 1,3-dichloro-5,5-dimethylhydantoin (NDDH) or trichloro- isocyanuric acid [Org Process Research & Development 2002,6,384-393], in an inert solvent, for example CCl4, chlorobenzene, or without solvents above 40°C and subsequently optionally purifying.
Preference is given to carrying out the reaction at 60-90°C, while chlorination on the aromatic ring is observed at lower temperatures than 40°C. The purification is preferably distillative or by a silica gel filtration.
The chlorine compounds of the formula (I) are only obtainable very inefficiently, if at all, by a ring-opening chlorination of the lactones (B), since the lactone structure is very stable. in addition, the 2-chioromethylbenzoic a 5 acid derivatives can surprisingly be distilled, can be isolated by this method in excellent chemical purity and do not react spontaneously in the course of storage to give the lactones.
A conversion of the chlorine compounds of the formula (1) to more reactive bromine or iodine compounds may likewise be advantageous, in order to increase the reactivity of this molecular building block in the further synthesis (for example to give PPAR agonists (C)). However, these compounds then have the “technical” disadvantages mentioned in the introduction. The conversion of the chlorine into the bromine or iodine compound is effected with alkali metal halides in inert solvents, preferably with sodium bromide or iodide in acetone under reflux. Alternatively, the transhalogenation and the further synthesis can also be carried out as a one-pot method with catalytical or stoichiometric amounts of alkyl halide, based on the chlorine compound used.
The present invention further provides a process for preparing the compounds of the formula (C)
R! oO
R"
DE
OL,-©
COR
C
(C) in which
R is H, C4-Cq2-alkyl, C3-Cg-cycloalkyl, Cg-C12-aryl, C1-C4-alkyl-Cg-
Cq2-aryl or Cs-C1p-heteroaryl and, in alkyl and cycloalkyl, one or more CH2 groups may be replaced by —O- and alkyl, cycloakyl and aryl may be substituted by halogen,
Y is -(CH2)3-, 1,3-phenylene, 1,3-cyciohexanediyl,
R’ is H, F, Br, CF3, (C1-Cg)-alkyl, O-(C1-Cg)-alkyl, phenyl;
R” is H, (C4-Cg)-alkyl, (C1-C3)-alkylphenyl, (Cs-Cg)-cycloalkyl, phenyl,
CFs;
zc 6 which comprises reacting compounds of the formula (C1)
R' 0
R" \
N
HO. 0 (C1) where Y, R’ and R” are each as defined above with compounds of the formula (1)
Ql.
CO,R ( where R is as defined above in toluene, NMP or other aprotic solvents, in the presence of a suitable base, preferably with potassium tert-butoxide, at from -78 to +50°C, preferably at from -30 to +20°C, and subsequently working up extractively and optionally crystallizing the end product.
The compounds of the formula (I) are notable for high stability compared to the corresponding bromine compounds. When the stability of methyl 2-bromomethyl-6-methylbenzoate is compared to that of the analogous chlorine compound, the following result is obtained: methyl 2-chloromethyl- 6-methylbenzoate can be distilled without decomposition at 66-77°C/0.1 mbar, and only a bottom temperature of above 120°C leads to significant lactone formation. At room temperature, it can be stored stably over several months. The storage stability of methyl 2-bromomethyl-6-methylbenzoate differs distinctly from this. At room temperature, the content of the bromine
: 7 2005/086499 compound reduces sharply within a few days, within one week from 92.6 to 81.0%, within 2 weeks to 67.8% and within 2 months to 7.8%. At the same time, the lactone content rises from 1.9% via 13.9% after 1 week and 89.5% in 2 months.
The following examples are cited without restriction to them:
Example 1:
Synthesis of methyl 2-chloromethyl-6-methylbenzoate 11.9 g of methyl 2,6-dimethylbenzoate are initially charged in 50 ml of chlorobenzene admixed at room temperature with 8.2 g of sulfuryl chloride and 40 mg of AIBN. The mixture is stirred at 60-90°C for 2 h. Afterwards, the mixture is admixed with 80 ml of saturated NaHCO3 solution. After the phase separation, the organic phase is washed with 100 ml of 10%
Na2SO03 solution, the organic phase is dried over magnesium sulfate and the chlorobenzene is distilled off in vacuo. 15.5 g of colorless liquid are obtained. The product is distilled under high vacuum (0.1 mbar, 66-77°C).
Yield: 10.2g (71% of theory; 95.2 area%).
Example 2:
Synthesis of isopropyl 2-chloromethyl-6-methylbenzoate 19.2 g of isopropyl 2,6-dimethylbenzoate are initially charged in 100 ml of carbon tetrachloride admixed at room temperature with 13.3g of
N-chlorosuccinimide and 200 mg of AIBN. The mixture is heated to reflux for 3 h. After the mixture has been cooled, it is filtered with suction and the succinimide is washed with 20 ml of carbon tetrachloride. The filtrates are combined and carbon tetrachloride is distilled off in vacuo. 21.8 g of color- less liquid are obtained. The product is distilled under high vacuum (0.05 mbar, 94-97°C). Yield: 13.9 g (61% of theory; 93.6 area%).
Example 3:
Synthesis of 2-methoxyethyl 2-chloromethyl-6-methylbenzoate 10.4 g of 2-methoxyethyl 2,6-dimethylbenzoate are admixed at room temperature with 5.4 g of sulfuryl chloride and 40 mg of AIBN. The mixture is stirred at 60-90°C for 1-2 h. Afterwards, the mixture is admixed with 20 ml of water, the phases are separated and the organic phase is dried over magnesium sulfate. The product is distilled under high vacuum (0.02 mbar, 95-103°C). Yield: 6.4 g (66% of theory; 91.8 area%).
Example 4:
Synthesis of benzyl 2-chloromethyl-6-methylbenzoate 12.0 g of benzyl 2,6-dimethylbenzoate are initially charged in 50 ml of carbon tetrachloride admixed at room temperature with 5.4 g of sulfuryl chloride and 40 mg of AIBN. The mixture is stirred at reflux for 4-5 h.
Afterwards, it is admixed with 40 ml of saturated NaHCO3 solution. After the phase separation, the organic phase is washed with 50 mi of 10% sodium sulfite solution and the organic phase is dried over magnesium sulfate. The product-containing solution is filtered through silica gel and washed again with 20 ml of carbon tetrachloride. After distilling off the solvent in vacuo, the product obtained is a bright yellow oil. Yield: 8.0 g (73% of theory; 88.4 area%).
Example 5: 2-Methyl-6-[3-(2-phenyloxazol-4-ylmethoxy)propoxymethyllbenzoic acid 4.8 g of methyl 2-chloromethyl-6-methylbenzoate are dissolved at room temperature in 250 ml of acetone and admixed with 35 g of sodium iodide.
The mixture is heated to reflux for 6 h. Subsequently, the solvent is removed at 0°C in vacuo. The residue is analyzed by means of LC-MS (87.7 area% of methyl 2-iodomethyl-6-methylbenzoate) and dissolved in 20 mi of toluene. The solution is added dropwise at -20°C within 10 min to a mixture of 5.0 g of 3-(2-phenyloxazol-4-ylmethoxy)propan-1-ol, 4.8 g of potassium tert-butoxide and 30 ml of toluene. Afterwards, the mixture is stirred at -20°C for 6 h and diluted with 100 ml of water, and the aqueous phase is removed. The organic phase is admixed with 40 ml of NMP and 10 ml of 32% sodium hydroxide solution and heated to reflux for 8 h on a water separator. Subsequently, the mixture is admixed with 100 ml of water and extracted twice with 25 ml of MTB ether each time. The aqueous phase is acidified with 5 ml of acetic acid and extracted twice with 50 ml of ethyl acetate each time. After the phases have been separated, the organic phase is dried over magnesium sulfate and the solvent is removed in vacuo. After the crystallization from diisopropyl! ether, 4.2 g of 2-methyl-6- [3-(2-phenyloxazol-4-ylmethoxy)propoxymethyllbenzoic acid (50% of theory, 99.2 HPLC area%) are obtained.

Claims (8)

10 2004/085377 9 PCT/EP2004/002579 What is claimed is:
1. A compound of the formula (I) JO CO,R (1) where R is H, C4-Cq2-alkyl, C3-Cg-cycloalkyl, Cg-C12-aryl, C1-C4- alkyl-Cg-C+2-aryl or Cs-Cqg-heteroaryl, and, in alkyl and cycloalkyl, one or more CH2 groups may be replaced by -O-, and alkyl, cycloalkyl and aryl may be substituted by halogen.
2. A compound of the formula (I) as claimed in claim 1 in which : R is C1-Cg alkyl, C3-Cg-cycloalkyl or C4-Cs-alkyl-Cg-C12-aryl, each of which may optionally be substituted by halogen and in which one or two CH groups may be replaced by -O-.
3. A compound of the formula (1) as claimed in claim 1 or 2 in which R is C1-Cg alkyl or C1-C4-alkyl-Cg-C42-aryl, each of which may optionally be substituted by halogen and in which one CH» group may be replaced by -O-.
4, A compound of the formula (I) as claimed in claims 1 to 3 in which R is methyl, ethyl, propyl, i-propyl, t-butyl, phenyl, 2-methoxy- ethyl or benzyl.
5. A process for preparing the compounds of the formula (I) as claimed in claims 1 to 4, which comprises reacting dimethylbenzoic esters of the formula (11)
CO,R (i where R is as defined above with a chlorinating reagent in an inert solvent or without solvents above 40°C and subsequently optionally purifying.
6. A process for preparing the compounds of the formula (C) rR 0) R" bs OLy-© COR (C) in which R is H, C4-Cq2-alkyl, C3-Cg-cycloalkyl, Cg-Cq2-aryl, C4-C4- alkyl-Cg-C12-aryl or Cs-C1p-heteroaryl and, in alkyl and cycloalkyl, one or more CH2 groups may be replaced by —-O- and alkyl, cycloakyl and aryl may be substituted by halogen, Y is -(CH2)3-, 1,3-phenylene, 1,3-cyclohexanediyl, R' is H, F, Br, CF3, (C1-Cg)-alkyl, O-(C4-Cg)-alkyl, phenyl; R” is H, (C1-Cg)alkyl, (C1-C3)-alkylphenyl, (Cs-Cg)-cycloalkyl, phenyl, CF3; which comprises reacting compounds of the formula (C1)
oo 11 - 2005/064889 R' 0] R" ba HOO (C1) where Y, R' and R"” are each as defined above with compounds of the formula (I) JO COR where R is as defined above in toluene, NMP or other aprotic solvents, in the presence of a suitable base, at -78 to +50°C, and subsequently working up extractively and optionally crystallizing the end product.
7. The process for preparing the compounds of the formula (C) as claimed in claim 6, wherein the phenyl ring is substituted by R’ in the m- or p-position.
8. The use of the compounds of the formula (I) as claimed in claims 1 to 4 for preparing PPAR agonists of the general formula (C).
ZA200506499A 2003-03-25 2005-08-15 Synthesis of 2-cholormethyl-6-methylbenzoic acid esters ZA200506499B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10313228A DE10313228A1 (en) 2003-03-25 2003-03-25 Synthesis of 2-chloromethyl-6-methylbenzoic acid esters

Publications (1)

Publication Number Publication Date
ZA200506499B true ZA200506499B (en) 2006-07-26

Family

ID=33015963

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200506499A ZA200506499B (en) 2003-03-25 2005-08-15 Synthesis of 2-cholormethyl-6-methylbenzoic acid esters

Country Status (25)

Country Link
EP (1) EP1611083B1 (en)
JP (1) JP4510805B2 (en)
KR (1) KR20050116388A (en)
CN (1) CN100378065C (en)
AR (1) AR043752A1 (en)
AT (1) ATE374742T1 (en)
AU (1) AU2004224177B2 (en)
BR (1) BRPI0408653A (en)
CA (1) CA2519715A1 (en)
CO (1) CO5690546A2 (en)
CY (1) CY1107029T1 (en)
DE (2) DE10313228A1 (en)
DK (1) DK1611083T3 (en)
ES (1) ES2293237T3 (en)
HK (1) HK1087098A1 (en)
IL (1) IL171031A (en)
MX (1) MXPA05010001A (en)
NO (1) NO20054875L (en)
NZ (1) NZ542603A (en)
PL (1) PL1611083T3 (en)
PT (1) PT1611083E (en)
RU (1) RU2345982C2 (en)
TW (1) TW200502213A (en)
WO (1) WO2004085377A1 (en)
ZA (1) ZA200506499B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005029382B3 (en) * 2005-06-24 2006-12-21 Sanofi-Aventis Deutschland Gmbh New alkoxymethylyl substituted benzoic acid derivatives are peroxisome proliferation activated receptor agonists used for treating and/or preventing e.g. diabetes mellitus, dyslipidemia and disturbances in fatty acid metabolism
CN114805120A (en) * 2022-05-23 2022-07-29 江苏瑞达环保科技有限公司 Synthesis process of m-cyanomethyl benzoate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4689425A (en) * 1986-11-06 1987-08-25 Stauffer Chemical Company Photochlorination of aromatic compounds in the side chain
ATE368037T1 (en) * 1999-04-28 2007-08-15 Sanofi Aventis Deutschland DI-ARYL ACID DERIVATIVES AS PPAR RECEPTOR LIGANDS
BR0010126A (en) * 1999-04-28 2002-02-26 Aventis Pharma Gmbh Tri-aryl acid derivatives as ppar receptor ligands
ES2278077T3 (en) * 2001-08-31 2007-08-01 Sanofi-Aventis Deutschland Gmbh DERIVATIVES OF DIARILCICLOALQUILO, PROCEDURE FOR ITS PREPARATION AND ITS USE AS PPAR ACTIVATORS.

Also Published As

Publication number Publication date
JP2006521307A (en) 2006-09-21
ATE374742T1 (en) 2007-10-15
BRPI0408653A (en) 2006-03-07
CN100378065C (en) 2008-04-02
DE10313228A1 (en) 2004-10-21
PT1611083E (en) 2007-11-26
RU2345982C2 (en) 2009-02-10
EP1611083B1 (en) 2007-10-03
NO20054875D0 (en) 2005-10-21
JP4510805B2 (en) 2010-07-28
DK1611083T3 (en) 2008-01-21
AR043752A1 (en) 2005-08-10
CN1759092A (en) 2006-04-12
IL171031A (en) 2010-11-30
MXPA05010001A (en) 2005-11-17
RU2005132827A (en) 2006-02-10
TW200502213A (en) 2005-01-16
CO5690546A2 (en) 2006-10-31
PL1611083T3 (en) 2008-01-31
NO20054875L (en) 2005-12-27
ES2293237T3 (en) 2008-03-16
EP1611083A1 (en) 2006-01-04
CA2519715A1 (en) 2004-10-07
AU2004224177B2 (en) 2010-01-21
WO2004085377A1 (en) 2004-10-07
KR20050116388A (en) 2005-12-12
DE502004005137D1 (en) 2007-11-15
CY1107029T1 (en) 2012-09-26
HK1087098A1 (en) 2006-10-06
NZ542603A (en) 2007-12-21
AU2004224177A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
RU2378261C2 (en) Method of preparing salt compound (4,5-dihydroisoxazol-3-yl)thiocarboxamidine
US11180443B2 (en) Preparation method for m-diamide compounds
US6222060B1 (en) Process for preparing o-(carboalkoxy)phenylmethanesulfonyl chloride derivatives
ZA200506499B (en) Synthesis of 2-cholormethyl-6-methylbenzoic acid esters
US6989462B2 (en) Synthesis of 2-chloromethyl-6-methylbenzoic ester
JPH04244041A (en) Process for producing halogenomethyl ketone especially 1,1,1-trifluoroacetone
JPH05262734A (en) Production of 5-substituted 2-chloropyridines
US20040171863A1 (en) Process for poducing beta-oxonitrile compound or alkali metal salt thereof
JP2595605B2 (en) Method for producing 2-substituted oxyimino-3-oxobutyric acid
US7078543B2 (en) Methods for producing oxirane carboxylic acids and derivatives thereof
HU216340B (en) A process for the preparation of 2,4,5-tribromopyrrole-3-carbonitrile
JP2730611B2 (en) Process for producing optically active hydroxycarbonyl halides
JP4165110B2 (en) Preparation of 4-oxypyrimidine derivatives
US4633013A (en) Preparation of α-haloacetoacetic esters
JP3148226B2 (en) Process for preparing isoxazole-4,5-dicarboxylic acid diesters and diesters of this kind
JPH0672987A (en) Production of methanesulfonyl fluoride derivative
HUT75713A (en) Process for producing 5-aryl-2,4-dialkyl-3h-1,2,4-triazol-3-thion derivatives
KR0135516B1 (en) Process for the preparation of 3-phenylpyrrole derivatives
KR100322237B1 (en) Process for preparing α-ketocarboxylic acid derivatives
JP2675924B2 (en) Method for producing aminoketones
JPS61293979A (en) Production of 3-substituted-2-formylthiophene compound
JPH0692347B2 (en) Terphenyl derivative and method for producing the same
CZ140296A3 (en) Process for preparing salts of 2-fluorocyclopropylaminesulfonic acid and chemical compound 2-fluorocyclopropylisocyanate
JPH1045762A (en) Production of oxotetrahydroindolizine derivative
JPH0672958A (en) Production of trans-beta-acylacrylic ester derivative